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Biological macromolecules including DNA, RNA, and proteins, have intrinsic features that make
them potential building blocks for the bottom-up fabrication of nanodevices. RNA is unique in
nanoscale fabrication due to its amazing diversity of function and structure. RNA molecules can be
designed and manipulated with a level of simplicity characteristic of DNA while possessing versatility
in structure and function similar to that of proteins. RNA molecules typically contain a large variety
of single stranded loops suitable for inter- and intra-molecular interaction. These loops can serve
as mounting dovetails obviating the need for external linking dowels in fabrication and assembly.
The self-assembly of nanoparticles from RNA involves cooperative interaction of individual RNA
molecules that spontaneously assemble in a predefined manner to form a larger two- or three-
dimensional structure. Within the realm of self-assembly there are two main categories, namely
template and non-template. Template assembly involves interaction of RNA molecules under the
influence of specific external sequence, forces, or spatial constraints such as RNA transcrip-
tion, hybridization, replication, annealing, molding, or replicas. In contrast, non-template assembly
involves formation of a larger structure by individual components without the influence of external
forces. Examples of non-template assembly are ligation, chemical conjugation, covalent linkage, and
loop/loop interaction of RNA, especially the formation of RNA multimeric complexes. The best char-
acterized RNA multiplier and the first to be described in RNA nanotechnological application is the
motor pRNA of bacteriophage phi29 which form dimers, trimers, and hexamers, via hand-in-hand
interaction. phi29 pRNA can be redesigned to form a variety of structures and shapes including
twins, tetramers, rods, triangles, and 3D arrays several microns in size via interaction of programmed
helical regions and loops. 3D RNA array formation requires a defined nucleotide number for twisting
and a palindromic sequence. Such arrays are unusually stable and resistant to a wide range of
temperatures, salt concentrations, and pH. Both the therapeutic siRNA or ribozyme and a receptor-
binding RNA aptamer or other ligands have been engineered into individual pRNAs. Individual
chimeric RNA building blocks harboring siRNA or other therapeutic molecules have been fabricated
subsequently into a trimer through hand-in-hand interaction of the engineered right and left inter-
locking RNA loops. The incubation of these particles containing the receptor-binding aptamer or
other ligands results in the binding and co-entry of trivalent therapeutic particles into cells. Such
particles were subsequently shown to modulate the apoptosis of cancer cells in both cell cultures
and animal trials. The use of such antigen-free 20–40 nm particles holds promise for the repeated
long-term treatment of chronic diseases. Other potentially useful RNA molecules that form multi-
mers include HIV RNA that contain kissing loop to form dimers, tecto-RNA that forms a “jigsaw
puzzle,” and the Drosophila bicoid mRNA that forms multimers via “hand-by-arm” interactions.
Applications of RNA molecules involving replication, molding, embossing, and other related tech-
niques, have recently been described that allow the utilization of a variety of materials to enhance
diversity and resolution of nanomaterials. It should eventually be possible to adapt RNA to facilitate
construction of ordered, patterned, or pre-programmed arrays or superstructures. Given the poten-
tial for 3D fabrication, the chance to produce reversible self-assembly, and the ability of self-repair,
editing and replication, RNA self-assembly will play an increasingly significant role in integrated
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biological nanofabrication. A random 100-nucleotide RNA library may exist in 16×1060 varieties
with multifarious structure to serve as a vital system for efficient fabrication, with a complexity and
diversity far exceeding that of any current nanoscale system.
This review covers the basic concepts of RNA structure and function, certain methods for the
study of RNA structure, the approaches for engineering or fabricating RNA into nanoparticles or
arrays, and special features of RNA molecules that form multimers. The most recent development
in exploration of RNA nanoparticles for pathogen detection, drug/gene delivery, and therapeutic
application is also introduced in this review.
Keywords: RNA, Nanotechnology, Self-Assembly, RNA Application, phi29 pRNA.
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1. THE SUITABILITY OF RNA
FOR NANOTECHNOLOGY
The emergent field of nanotechnology generally involves
the characterization, manipulation, modification, and/or
assembly of organized materials on the nanoscale level,12
thereby helping to form supramolecular structures.3–5
These materials can then be used as building blocks for
the construction of larger devices and systems.
Living systems contain a wide variety of nanomachines
and other such ordered structures,6 including motors,7–14
arrays,15–17 pumps, membrane cores, and valves. The nov-
lty and ngenious design of such machines have helped
inspire the development of biomimetics for nanodevices.14
Much current research is being devoted to make these
machines as viable and effective as possible outside of
their native environment.18 Once this is achieved, these
nanodevices could be used in such applications as the
delivery of drugs19 and therapeutic macromolecules,20 the
gearing of other nanodevices for purposes such as nano-
electromechanical systems (NEMS),21 the driving of
molecular sorters, the building of intricate arrays and chips
for diagnostics, molecular sensors, and novel actuators22
in new electronic and optical devices.
Since biological macromolecules, including DNA,
RNA, and proteins, intrinsically have defined features at
the nanometer scale, they could serve as unique and pow-
erful building blocks for the bottom-up fabrication of
nanostructures and nanodevices. Both DNA and proteins
have been much more extensively studied with regard
to their potential for nanotechnological applications than
has RNA.23–34 What makes RNA particularly useful is
the amazing diversity evident in its functionality, which
can be directly attributed to the versatility present in its
structure.35–39 Most available models that delineate various
RNA functions such as transcription, translation, degrada-
tion, maturation, and the catalytic activity of ribozymes
are based on a specific RNA structure.40 Therefore RNA
is a particularly interesting candidate for nanotechnolog-
ical applications, since RNA molecules can be designed
and manipulated with both a level of simplicity charac-
teristic of DNA4142 and a versatile flexibility in struc-
ture and function similar to that of proteins. Typically,
RNA molecule contains large variety of single stranded
loops for inter- and/or inter-molecular interaction. These
loops can serve as mounting dovetails, thus external
linking dowels might not be needed in fabrication and
assembly.
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RNA molecules are polymers made up of hundreds,
thousands, or millions of nucleotides from four groups:
adenosine (A), cystidine (C), guanosine (G), and uridine
(U) (see Section 3). As to a 100-nucleotide RNA polymer,
as many as 4100 (=1.6× 1060) different RNA molecules
can be designed. Since the size of RNA ranges from the
angstrom to the nanometer scale, bottom-up approaches
would be reasonable for use with RNA in nanotechnolog-
ical applications. The first application in RNA nanotech-
nology is the construction of micrometer-scale RNA arrays
derived from the nanometer-scale building block of bacte-
riophage phi29 motor pRNA.43
2. GENERAL APPROACHES IN BOTTOM UP
ASSEMBLY USING RNA
AS BUILDING BLOCKS
The self-assembly of nanoparticles from RNA is a promi-
nent bottom-up approach to obtain nanoscale, nanostruc-
tured materials, and thus represents an important approach
by which biological techniques and biomacromolecules
can be successfully integrated into nanotechnology.43–47
Such approaches rely upon the cooperative interaction of
individual RNA molecules that spontaneously assemble
in a predefined manner to form a larger two- or three-
dimensional structure. Within the realm of self-assembly
here are two main subcategories: templated assembly and
nontemplated assembly. Templated assembly involves the
interaction of RNA with one another under the influ-
ence of a specific external force, structure, or spatial
Dr. Guo is a Professor of Molecular Virology and Biomedical Engineering at Purdue Uni-
versity where he serves as the Director of the Lab of Gene Therapy. His research expertise
lies in viral DNA packaging and RNA biochemistry. He has been working on bottom-up
assembly of biomacromolecules in nanoscale for more than twenty years. For example, he
constructed an in-vitro phi29 DNA packaging motor (the most powerful biomotor studied to
date) (PNAS, 1986); discovered the motor pRNA (the viral RNA that binds ATP) (Science,
1987); and served as the guest editor of the Journal Viral Assembly in 1994. However,
he has not used the word “nanotechnology” until recently. Other pioneering work includes
his demonstration that RNA can serve as building blocks for the construction of devices
in nanotechnology. His latest contribution is the application of RNA nanotechnology for
gene or drug delivery to treat cancers and viral-related diseases and for pathogen detection.
His lab is the first to assemble infectious dsDNA virions in the test tube using synthetic components and purified
recombinant nanomotors. His finding that pRNA binds ATP and forms a hexamer to gear the phi29 DNA-packaging
motor suggests that RNA might play a role that protein enzymes (such as helicase) play. His research effort has led
to an NIH “First Award” in 1992, the “Pfizer Distinguished Faculty Award for Research Excellence” in 1995, the
“Purdue Faculty Scholar” in 1998, and the “Seed Award” in 2004. Dr. Guo came to the United States at the end of
1983. He finished his Ph.D. training in Microbiology and Genetics in Dr. Dwight Anderson’s lab at the University of
Minnesota/School of Dentistry in May of 1987. He was a postdoctoral fellow with Dr. Enzo Paoletti in Wadsworth
Center and later a visiting scientist with Dr. Bernard Moss—a member of National Academy of Sciences at NIH. He
joined Purdue in 1990 and became a full Professor in 1997. His lab has been affiliated with a number of interdisciplinary
programs including Genetics, Biochemistry and Molecular Biology, Virology, the Cancer Research Center, Veterinary
Pathobiology, Nanotechnology, and Biomedical Engineering. He also founded the Purdue Graduate Program in Viral
Research. He has also chaired and been the keynote speaker at many international conferences. He is an editor or editorial
board member for six journals, including four in nanotechnology and bionanotechnology. He published 70 original
papers in high impact refereed journals including Science, PNAS, and Molecular Cell.
constraint. RNA transcription, hybridization, replication,
annealing of DNA and RNA, molding, or replica, are
part of this category. Nontemplated assembly involves the
formation of a larger structure by individual components
without any influence from external forces. Included in the
nontemplated category are ligation, chemical conjugation,
covalent linkages, loop/loop interaction of RNA, and the
formation of macromolecules by structural interaction in
the formation of multimers.414346–49
One of the main areas of interest in current nanotechnol-
ogy is the synthesis of patterned arrays50–53 for technologi-
cal applications. Arrays can be engineered to serve as chips
in the diagnosis of diseases or to function as ultrahigh
density data storage systems.21 Ordered nanocrystals have
already been assembled into superlattices by techniques
such as colloidal crystallization,54–56 macromolecule self-
assembly,1157–59 complementary interactions,486061 and
patterned etch pits.62 Ordered biological structural arrays
can serve as templates for the further construction of
superlattices.11575863 Bacteriophage phi29 pRNA has
been used as building blocks for the construction of RNA
arrays with the size in micron.43
Various applications involving replication, molding,
embossing, and other related techniques have recently been
emerging,45 allowing for the utilization of a variety of
materials to improve the diversity and to enhance the res-
olution of nanomaterials. It may eventually be possible
to specifically adapt RNA for use in many of these tech-
niques, which would facilitate the construction of ordered,
patterned or preprogrammed arrays or superstructures. It is
1966 J. Nanosci. Nanotechnol. 5, 1964–1982, 2005
Delivered by Ingenta to:
Purdue University Libraries
IP : 128.46.220.88






Guo RNA Nanotechnology: Engineering, Assembly and Applications in Detection, Gene Delivery and Therapy
evident that RNA self-assembly will play an increasingly
significant role in integrated biological nanofabrication in
the future, given its potential for 3D fabrication, the chance
to produce reversible self-assembly, and the ability of
self-repairing and replicating. RNA serves as the ultimate
model for effective, efficient nanoscale self-assembly, with
a complexity far exceeding that of any current nanoscale
systems.
3. BASIC CONCEPTS OF RNA
STRUCTURE AND FUNCTION
Prior to a detailed description of the wide range of appli-
cations of RNA nanotechnology, it is important to provide
some basic background information regarding RNA and
its specific attributes. Following is a brief discussion of its
process of formation and structural characteristics.
Nucleotides form the basic building blocks of ribonu-
cleic acid (RNA). These nucleic acids are composed of
three main components: (1) a base, (2) a phosphate group,
and (3) a pentose (a five-carbon sugar ribose). In chemical
terms, the two most important differences between RNA
and DNA are: (1) the presence of an –OH group at the
2′ position of the ribose in RNA and the absence of the
oxygen of this group in DNA (hence the deoxy—prefix)
and (2) the replacement of the uracil base (U) in RNA
by the thymine base (T) in DNA. When there is only a
base/pentose composite, this structure is called “nucleo-
side;” when phosphate is included, a nucleotide is formed.
The four nucleosides of RNA are adenosine (A), cystidine
(C), guanosine (G), and uridine (U).
RNA can be synthesized chemically or enzymatically
by RNA polymerases. In the latter case, nucleoside
monophosphates link the hydroxyl group of one nucleotide
to the phosphate of another during transcription. A tem-
plate strand directs insertion of the nucleoside monophos-
phate. In this manner, a long chain of nucleotides can be
formed, with one end of the chain (the 5′ end) having
one or up to three phosphates and the other (the 3′ end) a
free hydroxyl group. Along the length of the chain, there
are two sides. One side is known as the “backbone” and
consists of sugar and phosphate groups. The other side is
left open for the possibility of the base-pairing of chains.
This flexibility allows for the construction of a wide vari-
ety of complex structures and provides for a considerable
amount of functional diversity.
RNA will self-fold into 2D and 3D structure. A chain’s
relative level of stringency determines whether it exists in
a double-stranded form under conditions of low stringency
or a single-stranded form in a high stringency environ-
ment. Salt concentration is generally inversely proportional
to stringency, since the presence of only a small amount
of salt tends to cause the natural electrostatic repulsion
of the two strands to overcome any ionic attraction and
thus to manifest a single-stranded, high stringency con-
dition. In contrast, temperature is directly proportional
to the level of stringency; for example, a high tempera-
ture environment is likely to cause dissociation of dimer,
trimer, hexamer into monomer and any double-stranded
RNA structures into a single strand. Other conditions affect
stringency as well.
One of the RNA functions involves protein synthesis
within cells. There are a wide variety of subtypes of RNA
with different functions that have been identified. Among
the most common types are: (1) ribosomal RNA (rRNA),
which serves as the “machinery” in the process of syn-
thesis, (2) messenger RNA (mRNA), which is responsible
for the transmission of DNA information, and (3) transfer
RNA (tRNA), which performs a variety of specific roles
in protein synthesis. These and many other small RNA
subtypes, including small interfering RNA (siRNA),64–67
antisense RNA,6869 ribozymes,70–73 aptamer RNA,7475
pRNA (a viral packaging RNA discussed below),76 and
microRNA,77 have potential application in nanotechnol-
ogy, gene therapy, and other areas. Many of the small
RNAs from cells and other microorganisms exhibit novel,
emerging and/or unknown functions, and there is still
much to be learned in order to fully utilize their differing
mechanisms, function, and structure.
4. METHODS FOR THE STUDY OF
RNA STRUCTURE
Though nucleotide derivatives have been found in RNA,
the primary sequence of the RNA molecule is as simple
as DNA, since both are composed of four nucleotides.
Both DNA and RNA can form double-helical structure, but
RNA has a more diverse structure. Even the smallest RNA
molecules, though they contain only the four nucleotides
A, G, C, and U, exhibit significant versatility in biological
function. Such versatility is ascribed to the flexibility and
complexity in RNA structural folding. NMR78–84 and X-ray
crystallography85–89 have been used to obtain a physical
tertiary structure of RNAs. Yet, the difficulty, uncertainty,
and time involved in obtaining a diffractable RNA crys-
tallographic structure, together with the difficulty of using
NMR for large RNAs, necessitate the use of alternative
approaches to obtain information on RNA structures.
4.1. Genetic Analysis by Truncation, Insertion,
Deletion, and Mutation
Mutant RNAs can be easily constructed through the trun-
cation, deletion, insertion, and mutation targeting of any
desired position. For example, using an in vitro assembly
assay system, dozens of mutant phi29 pRNAs can be pro-
duced and tested in one to two weeks.5990–93
4.2. Phylogenetic Analysis
Phylogenetic analysis of RNA can be used to compare
the sequences of RNA molecules with similar or identical
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functions from different species.94–97 The supposition that
RNA molecules with a similar function possess a common
secondary structure has been deduced from such analyses.
It has been found that RNA structure plays a critical role
in RNA function and that nature most often tends to select
the most stable molecule with the best-fit structure or with
acceptable base co-variations. Such phylogenetic analysis
of species from nature can potentially be expanded into
molecules made artificially, such as those made by the
use of complementary modification or SELEX (described
below).
4.3. SELEX
The SELEX (Systematic Evolution of Ligands by Expo-
nential Enrichment) method has permitted the identifi-
cation of unique RNA/DNA molecules from very large
populations of random sequences DNA or RNA libraries.
Usually, selections are frequently carried out with RNA
pools due to the folding ability of RNAs into complex
structures which can be a source of diversity of RNA
function.7598–101 SELEX allows screening for co-variation
of several nucleotides and can be used to reveal non-
canonical interaction which is difficult to prove by classic
genetic and biochemical approaches.7598–101 For example,
SELEX has been used to select pRNA sequences that bind
procapsids102 and proved that pRNA can bind ATP.103
4.4. Complementary Modification
One approach often utilized to confirm base-pairing in
predicted RNA structure is complementary modification.
Before the conclusion that “G pairs to C” in an RNA
structure can be definitively drawn, at least three mutants
should be constructed and analyzed. These mutants, hav-
ing either one G changed to A (or U) or one C to U
(or A) should render the mutant inactive. When both Gs
are changed to As (or Us) and both Cs are changed to Us
(or As), the mutant should experience restored activity. For
example, the complementary modification helps the study
of loop/loop interaction in pRNA dimer formation.40104105
4.5. Chemical Modification and Chemical
Modification Interference
Chemical modification is often employed to probe RNA
structure.106107 The modifying agents utilized include
dimethyl sulfate (DMS), which methylates A at N1, G at
N7, and C at N3;108109 kethoxal, which modifies G at N1
and N2;110111 and 1-cyclohexyl-3-(2-morpholinoethyl)-
carbodiimide metho-p-toluene sulfonate (CMCT), which
attacks U at N3 and G at N1. The locations of modified
bases can be identified by primer extension with reverse
transcriptase.108112 The successful chemical modification
of a base is a good indication that the base is unpaired
and that the specific functional group is solvent-exposed.
Thus this base is a possible candidate for intermolecular
interactions. A lack of modification will most likely be due
to base pairing, especially in helical regions, but may also
be the result of tertiary interactions or non-canonical base–
base, base–sugar, or base–phosphate interactions in loop
or bulge regions.110 Such chemical modification data can
provide information regarding base accessibility, which
is helpful in assessing and predicting secondary struc-
tures, evaluating 3-D molecular models, and analyzing
RNA/protein interactions.
Chemical modification interference113–115 involves the
same procedure as chemical modification; the general prin-
ciple behind the interference method is that an RNA con-
taining an interfering modified base would appear in the
fast migrating monomer band, while RNA containing a
non-interfering modified base would appear in the slower
migrating dimer band.
4.6. Photoaffinity Crosslinking by Psoralen,
GMPS/Aryl Azide, Phenphi, or Ultraviolet-Light
The chemical psoralen can intercalate into RNA or DNA
helices and after irradiation with 320–400 nm light, freeze
(in a helical or pseudoknot form) the uridines of RNA or
the thymidines of DNA by covalent attachment116 if they
are in close proximity.117–120 The sites of crosslinks can
be determined by primer extension121 and/or Mung bean
nuclease treatment.122 The psoralen derivative, AMT (4′-
aminomethyl-4,5′,8-trimethyl psoralen), is a good choice
to crosslink RNA due to its solubility.121 Psoralen cross-
links only RNA or DNA but not protein, which is different
from the azido group (see below) which crosslinks non-
specifically to both protein and nucleic acids. Psoralen can
induce intra-molecular crosslinks within the RNA even in
the presence of other proteins and RNA conformations in
different environments can therefore be detected.
Aryl azides contain functional groups that are chemi-
cally inert in the absence of light, but can be converted
to a reactive nitrene after long wavelength UV irradia-
tion which then inserts into nearby bonds resulting in
covalent crosslinks.123124 Thus, aryl azides can be incor-
porated into RNA to obtain structural data.125126 Spe-
cific internal bases of RNA can be uniquely labeled
with photoaffinity crosslinking agents to analyze inter-
and intra-molecular interactions. Crosslinked RNAs are
separated from uncrosslinked RNAs by denaturing gel
electrophoresis. Crosslink sites are determined by primer
extension.113127 Bases identified as crosslink sites by
primer extension indicate that these bases are in close prox-
imity to the photoagent-labeled base. Crosslinking is used
to determine the proximity in 3D structure determination.
Unlike psoralen, phenphi [(cis-Rh(phen)(phi)Cl+2
(phen = 1,10-phenanthroline; and phi = 9,10-phenanthren-
equinone diimine)] induces covalent bonds between
guanosine bases upon UV activation. Phenphi has also
been shown to crosslink RNA.128
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Also, ultraviolet-induced cross-linking of RNA to pro-
tein or RNA to RNA has been proved to be an effective
methods for the study of RNA protein interaction and RNA
structure–function relationships.129
4.7. Cryo-Atomic Force Microscopy (Cryo-AFM)
Cryo-AFM130 can be performed to better elucidate the
3-D structure of RNA in native conformation.113131132 The
color indicates the thickness or height of the sample but
does not reflect the atomic density observed. The brighter
the color indicates the thicker of the sample—the darker
the color, the thinner the sample (Fig. 3).
4.8. Computer Modeling of RNA’s
Three-Dimensional Structure
Once data is collected from such methods as crosslink-
ing, chemical probing, chemical modification, chemical
modification interference, and cryo-AFM, in addition to
other methods, computer programs can be used to effec-
tively translate the data into three-dimensional cons-
tructions.133–135 Programs such as NAHELIX, MANIP,
PRENUC, NUCLIN, and NUCMULT136137 can be used to
model structures based on such data and constraints. Mod-
ified distance geometry and molecular mechanics algo-
rithms using simplified “pseudo atom” representations can
be used to generate structures consistent with data from
various techniques. A constraint satisfaction algorithm is
combined with discrete representations of nucleotide con-
formations to refine the disturbed area in order to ensure
the normal representation of all atoms.138
4.9. Ribonuclease Probing
Some ribonucleases are specific to RNA secondary
structure.110122139 For example, RNases T1 (specific for
GpN linkages), U2 (specific for ApN linkages), and S1
prefer to cleave single-stranded RNA. Nuclease V1 is spe-
cific for double stranded RNA. End-labeled RNA in var-
ious solutions with or without containing Mg++ can be
probed by T1, U2, or V1 nucleases.94121 T1 and V1 can be
used to distinguish the loops and helices. In addition, T1
nuclease can be used to study changes in RNA conforma-
tion. Since the activity of RNase T1 is Mg++ independent,
this enzyme can also be used to investigate the conforma-
tional change of RNA in the presence or absence of Mg++
[Ref. 121], Besides end labeling, the cleavage site can also
be identified by primer extension or 2D gel analysis.
4.10. Footprinting
Foot printing is a technique derived from nuclease prob-
ing or chemical modification and is particularly use-
ful in probing the interaction of RNA with proteins.140
The procapsid/pRNA complex has been probed with
nucleases A, T1, and V1.141 The RNA will be end-labeled,
for example, with 32P and the optimal concentration of
enzymes is determined empirically to ensure, on the aver-
age, one cleavage site per RNA molecule. Alternatively,
the results will be analyzed by primer extension or 2D gel
analysis.
4.11. Other Methods
Besides, other methods for RNA structure study are avail-
able. For example, lead (II) cleavage has previously been
used to probe tRNA structure142 and now developed
to investigate RNA structure in vivo.143 Hydroxyl radi-
cal footprinting can provide information of the solvent-
accessible area of a folded RNA molecule.144 Nucleotide
analog interference mapping make it possible to determine
the chemical basis of RNA function and structure.145 Fluo-
rescence techniques, in particular, fluorescence resonance
energy transfer (FRET), have been employed to monitor
RNA conformational changes.146147 Also, enzymatic foot-
printing, electrophoresis mobility shift assay (EMSA)37
have been used for the studies on thermodynamics, RNA–
protein interaction or conformational change of RNA.
5. RNA MOLECULES THAT
FORM MULTIMERS
The diverse structure and processes of the many types of
RNA play a crucial role in determining the functional-
ity of a variety of organisms. Understanding the specific
attributes and conformations of these types of RNA will
lead to advances in medicine and nanotechnology. Fol-
lowing are some prominent examples of different types of
RNA that form multimers by RNA–RNA interaction and
their potential applications. Such interaction can be uti-
lized for bottom-up assembly.
5.1. Motor pRNA of Bacteriophages phi29
A striking common feature in the maturation of all linear
ds-DNA viruses is that their genome is translocated into a
preformed protein shell.148–155 A DNA-translocating motor,
powered by ATP hydrolysis, accomplishes this energet-
ically unfavorable DNA transportation process. A RNA
molecule called pRNA has been shown to have a novel and
indispensable role in phi29 DNA packaging motor.76156
pRNA contains two functional domains (Fig. 1).154157
The procapsid binding domain is located at the central
region91132141158 bases 23–97, while the DNA translo-
cation domain is located at the 5′/3′ paired ends.104
This conclusion comes from different studies includ-
ing (a) base deletion and mutation;93104105159160 (b)
ribonuclease probing;94121141159 (c) oligo targeting;161162
(d) competition assays to inhibit phage assembly;162–164
(e) UV-crosslinking;158 (f) psoralen crosslinking;121 and
(g) primer extension.131
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Fig. 1. Sequence and structural elucidation of phi29 motor pRNA and
related assemblages. (A) Primary and secondary structure of wild-type
pRNA I-i′. The binding domain (shaded area) and the DNA translocation
domain (the helical region) are marked with bold lines. The four bases
in the right and left loops, which are responsible for inter-RNA interac-
tions, are boxed. (B) Three-dimensional structure of wild-type pRNA I-i′
displayed as ribbon. (C) Diagrams depicting the pRNA monomer A-b′
with unpaired right/left loops. (D) pRNA dimers (A-b′)(B-a′). (E) pRNA
trimers (A-b′)(B-e′)(E-a′). (F) pRNA monomer with unpaired right/left
loops A-b′ and a 6-nucleotide palindromic sequence. (G) pRNA twin
A-b′. (H) Size and three-dimensional computer model of phi29 pRNA
trimer. Reprinted with permission from [43], D. Shu et al., Nano Lett. 4,
1717 (2004). © 2004, American Chemical Society.
The six pRNAs form a hexagon via intermolecular
base-pairing between the right loop (bases 42–45) and
the left loop (bases 82–85).163–168 pRNA dimers are the
building blocks in hexamer assembly. pRNA has many
attributes that make it a novel choice for nano-
technological applications (Figs. 1–4). Among these are
its ATP-binding activity,103 its function in driving the
DNA-packaging motor,154 its ability to form dimers,
trimers, and hexamers,48132165–167169 its tight and stable
folding,9193105135160 its two independent domains for
structure and function,104105141158 and its functional simi-
larity as compared to protein enzymes.76154 Since the size
of RNA ranges from the angstrom to the nanometer scale,
the bottom-up approach could be reasonably applied to
RNA in nanotechnological applications. Larger RNA com-
plexes can be constructed from the following three build-
ing blocks:
(i) Monomer with intramolecularly self-complementary
left and right loops.
(ii) Monomer with non-complementary left and right
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Fig. 2. Polyacrylamide gel showing monomers, dimers, trimers, twins,
tetramers, and arrays. (A) Native and denatured gel. (B) Test of the stabil-
ity of pRNA dimers under different conditions. Reprinted with permission
from [43], D. Shu et al., Nano Lett. 4, 1717 (2004). © 2004, American
Chemical Society.
(iii) Monomer with intermolecularly self-complementary
left and right loops and palindromic 3′ ends.
5.1.1. Nomenclature of RNA Subunits
To simplify the description in the construction of RNA
complexes, uppercase and lower case letters are used to
represent the right and left hand loops of the pRNA
respectively, (Fig. 1A). The matched letters indicate
complementarity, whereas different letters indicate non-
complementary loops. For example, pRNA(A-b′) contains
right hand loop A(5
′




U85G84C83G82), which can pair with the left hand loop




5.1.2. Construction of Dimers
Dimers are formed by the intermolecular interaction of
interlocking right and left loops. Alone, the pRNAs A/b′
and B/a′ were inactive in DNA packaging, but when mixed
together, DNA-packaging activity was restored.135166 This
result can be explained by the trans-complementarity of
the interlocking pRNA loops, i.e., the right-hand loop A
of pRNA A/b′ can pair with the left-hand loop a′ of pRNA
B/a′. Mixing two inactive pRNAs with interlocking loops,
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Fig. 3. Atomic force microscopy (AFM) showing pRNA monomers
(A), dimers (B), trimers (C), and arrays (D) of pRNA. The three insets
at the left of each panel contain images with higher magnification, as
indicated by the size of the frame. The pRNA monomers folded into a
checkmark shape, dimers displayed a rod shape, trimer exhibited trian-
gle shape, and arrays displayed as bundles. Formation of dimers requires
Mg2+, while the sample on mica was briefly rinsed with water before
freezing for cryo-AFM, which resulted in some dissociation of dimers or
trimers even when the pRNA was already adsorbed to the activated mica
surface. The color within each image reflects the thickness and height of
the molecule. The brighter or whiter, the color, the thicker or taller the
molecule; the darker the image, the thinner the molecule. Reprinted with
























Fig. 4. A mixture of two complementary twins, A-b′ and B-a′, assem-
bled into two distinct supramolecular structures. (A) Two complementary
twins were able to form a stable tetramer (double-twins) by assembling
into a circular structure. (B) Concatemers of alternating twins formed
when a twin interacted with two rather than one complementary twin.
Reprinted with permission from [43], D. Shu et al., Nano Lett. 4, 1717
(2004). © 2004, American Chemical Society.
such as when pRNA A-b′ and B-a′ are mixed in a 1:1
molar ratio, results in the production of pRNA dimers with
up to 100% efficiency. The fact that the three inactive
pRNAs are fully active when mixed together is not surpris-
ing, since the number of pRNAs in the DNA-packaging
complex is a multiple of 2 (six copies), in addition to being
a multiple of three. The mechanism of dimer formation
by interlocking loop/loop interaction will be utilized to
construct chimeric pRNA dimers carrying receptor-binding
RNA aptamer and/or therapeutic RNA molecules.
5.1.3. Construction of Trimers
Several sets of trimers were constructed, e.g., A-b′, B-c′,
and C-a′. Indeed, stable pRNA trimers are formed with a
very high efficiency, up to 100%, by using sets of three
interlocking pRNA.4348132166167 A mechanism similar to
that of dimer formation by interlocking loop/loop inter-
action is utilized to construct chimeric pRNA trimers43
carrying receptor-binding RNA aptamer and/or therapeu-
tic RNA molecules (see below). Nucleotides 23–97 are
the central components in the formation of both dimers
and trimers. The ability to form dimers or trimers is not
affected by 5′ or 3′ end truncation before residue #23 and
after residue #97, since one or two truncated or extended
pRNAs can be incorporated into dimers while one, two,
or three truncated or extended pRNAs can be incorpo-
rated into trimers. Specific nucleotide assignment before
#29 and after #92 is not required for trimer formation,
as long as the complementary helix at the 3′/5′ region is
generated.
Trimers are verified by native gel or analyzed by 10–
30% glycerol or 5–20% sucrose gradient sedimentation in
the presence of 10 mM magnesium. It has been shown that
monomers, dimers, and trimers were separated by sedi-
mentation. Plotting the hypothetical molecular weight vs
the log of migration distance (the fractional number) in
gradient revealed a linear relationship.170 Trimers can be
further confirmed by AFM imaging if necessary.
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5.1.4. Construction of Hexamers
Recently, an “annealing approach” has been employed to
assemble hexamer (unpublished data).
5.2. HIV RNA Dimer
HIV dimerization occurs through loop–loop interactions
between the stem loops of two identical RNA molecules
(Fig. 5). The resultant “kissing complex” refolds into a
more stable complex known as an extended dimer. Still,
little is known about the transitional pathway due to dif-
ficulties involved in directly observing the intermediate
processes.171–173 Understanding this pathway could lead to
significant improvements in the treatment of the disease
caused by the virus and the application of such RNA–RNA
interaction in nanotechnology.
5.3. TectoRNA
RNA has been formed into “jigsaw puzzle” pieces known
as tectosquares.174175 Their programming allows for the
production of nanoscale fabrics with controllable direc-
tionality and geometry41 (Fig. 5). In contrast to tradi-
tional materials, where materials are selected, rather than
designed, for a given application, the next generation of
materials will allow for the a priori design of novel build-
ing blocks, programmed for assembly and synthesized
with particular needs in mind.
5.4. mRNA Dimerization in Drosophila Embryos
The multilization of mRNA is of considerable impor-
tance for the localization of ribonucleoprotein particles in
Drosophila embryos.176177 Dimerization proceeds through
a two-step mechanism via a hand-in-arm interaction,
which includes a transition from the reversible initiation
complex into a very stable one.178179 A series of differ-
ent RNA fragments with the capacity to form a variety of
structures, including open dimers and closed dimers and
other multimers, were constructed.178–180 The initial open
dimer is converted into a stable closed dimer, perhaps due
to a kinetically-controlled mechanism.
6. APPLICATIONS OF RNA
NANOTECHNOLOGY IN MEDICINE
Nanotechnology has brought about an unprecedented vari-
ety of revolutionary approaches for the detection and
therapy of diseases. Due to their small size, nanoparticles
can readily interact with biomolecules either on the surface
or within cells. To take advantage of this, it is desirable
to develop multifunctional engineered, targeted complexes
capable of bypassing biological barriers to deliver multiple
therapeutic agents directly to specific cells or tissues. Due
to their easy access to many areas of the body, multivalent




Fig. 5. Model of HIV-1 RNA and TectoRNA structure. (A) HIV-1 RNA
secondary structure models. Model of the structural rearrangements in
the TAR hairpin. TAR dimerization induced by the nucleocapsid pro-
tein gives rise to a kissing-loop complex and an extended duplex. The
following sequences are marked: the central palindrome (red), extended
base-pairing (blue), and secondary parallel helix (green; gray dotted lines
in extended duplex). Adapted with permission from [216], E. S. Andersen
et al., J. Biol. Chem. 279, 22243 (2004). © 2004, American Society
for Biochemistry and Molecular Biology. (B) TectoRNAs employing two
loop-receptor motifs and their modes of assembly. (a) Two modes of
assembly used in this study. (b) Schematic of RNA assembly unit show-
ing elements varied for this study. The tetraloop (L) is shown in red, the
tetraloop receptor (R) in green, the linker (or hinge) in blue and the insert
[comprising a helix and a second linker (or hinge)] in magenta (refer also
to the 2D and 3D models in Figs. 2 and 3). Adapted with permission
from [175], L. Jaeger et al., Nucleic Acids Res. 29, 455 (2001). © 2001,
Oxford University Press.
the potential to combine detection and therapy in ways
previously unimaginable.
RNA molecular therapy is widely understood to be one
of the most promising applications of modern biological
science.181–185 There are many molecules that could poten-
tially be utilized for nanotechnology-based RNA therapy
such as small interfering RNA,65–67186 ribozymes7173184
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and anti-sense RNA6869 which all show significant poten-
tials to down-regulate specific gene expression in cancer-
ous or viral-infected cells.187 The successful application
of siRNAs and ribozymes for the treatment of cancer
and infectious diseases requires overcoming the follow-
ing obstacles: (1) the difficulty of entering the cell due to
the size limit for membrane penetration; (2) degradation
by exonucleases within the cell; (3) trafficking into the
appropriate cell compartment; and (4) correct folding of
the ribozymes or siRNA in the cell if fused to a carrier.
At this time, the development of a safe, efficient, specific,
and nonpathogenic nanodevice for the delivery of multiple
therapeutic RNAs is highly desirable.
6.1. Small RNA Molecule with
Therapeutic Potentials
6.1.1. siRNA188189
siRNA (short or small interfering RNA) are 20–25
nucleotide molecules of RNA that are produced when
larger pieces of RNA are cleaved. Their function is to
interfere with gene expression through the cleavage of
mRNA with homologous sequence by a protein/RNA com-
plex named RISC (RNA-induced silencing complex). An
enzyme known as Dicer facilitates this process, which,
as specified later in the gene therapy section of the
manuscript, has already exhibited significant nanotechno-
logical applicability.4647
6.1.2. Ribozyme70–73
Ribozymes are RNA molecules that have the capability
to catalyze chemical reactions. They have highly signif-
icant potential for therapeutic purposes190 since they are
capable of regulating gene function by intercepting and
cleaving messenger RNA or viral genomic RNA. Even
within the RNA subtype of ribozymes, there are signif-
icant structural and functional differences between dif-
ferent molecules; hammerhead ribozymes191 and hairpin
ribozymes192 are so named because of their appearance
when visualized by microscope. These are both catego-
rized as small ribozymes; larger ribozymes include introns
and RNase P.193194
6.1.3. Antisense RNA6869
Antisense RNA molecules function through connecting
with particular target RNAs in order to regulate their func-
tionality after transcription. They are called “antisense”
because most often they are transcribed in a direction
opposite that of the target RNA from the same DNA tran-
script. This allows for the production of a pair of tran-
scripts that are complementary or nearly complementary.
The combination of these two types of RNA produces a
stable and easily detectable complex, and thus antisense
RNA provides a promising route by which RNA/RNA
interactions can be reliably probed. A variety of types
of artificially produced antisense RNAs have been devel-
oped, and their applications for therapeutic purposes are
just beginning to be fully realized.
6.1.4. Aptamer759899195
Aptamers are a family of RNA- or DNA-based oligonu-
cleotides obtained by in vitro screening that bind to
selected targets, including proteins, organic compounds,
and nucleic acids.7599 Their usefulness is found in their
ability to recognize the ligands through the formation of
binding pockets analogous to antigen–antibody interaction.
SELEX is the method which screens for the aptamers from
these randomized RNA pools. Starting with a library con-
taining random RNA sequences with about 1014–17 vari-
eties of RNA molecules, in vitro binding, elution, and
reverse PCR amplification techniques allow for the selec-
tion of RNA molecules that efficiently bind to a specific
receptor or ligand with high affinity.196–199 Using this
technique, a number of aptamers that specifically recog-
nize many kinds of targets, such as organic compounds,
nucleotides, peptides, proteins, and receptors, have been
obtained.103199–203
6.2. The Uniqueness of Therapeutic Nanoparticles
Derived from phi29 pRNA
Until recently, the use of small RNA in gene therapy was
significantly hampered by the difficulties involved in pro-
ducing a safe and efficient system by which specific cells
could be targeted. Recently, phi29 pRNA has been used to
harbor small therapeutic RNA molecules4647 for the deliv-
ery to specific cancer cells (Fig. 6).
By utilizing RNA nanotechnology, both therapeutic
siRNA and a receptor-binding RNA aptamer was engi-
neered into individual pRNAs of phi29’s motor.4647 The
RNA building block harboring siRNA or other therapeu-
tic molecules was fabricated subsequently into a trimer
through the interaction of engineered right and left inter-
locking RNA loops.4348132166167 The incubation of the
protein-free nanoscale particles containing the receptor-
binding aptamer or other ligands resulted in the binding
and co-entry of the trivalent therapeutic particles into cells,
subsequently modulating the apoptosis of cancer cells and
leukemia model lymphocytes in cell culture and animal
trials. The use of such antigenicity-free 20–40 nm parti-
cles holds promise for the repeated long-term treatment
of chronic diseases. Such protein-free 30 nm nanoparticles
will allow for repeated long-term administration and avoid
problems of short retention time of small molecules less
than 30 nm and the difficulty of delivery of particles larger
than 100 nm.
In addition, since there are six chimeric pRNAs in the
hexamer, a polyvalent nanoparticle can be constructed by
utilizing six available positions to carry molecules for cell
recognition, therapy, and detection (Fig. 12). Besides the
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Fig. 6. Functional assay of chimeric pRNA/siRNA(GFP) by trans-
fection. (A), (B), and (C) are fluorescence microscopy images to
show the silencing of GFP gene by transfection. (A) Dose-dependent
silencing of GFP gene by chimeric pRNA/siRNA(GFP) (the left col-
umn). A mutant pRNA/siRNA on the right column served as neg-
ative control. (A) GFP expression of cells transfected with various
RNA. (a) No RNA; (b) Synthesized double-stranded siRNA(GFP);
(c) Double-stranded siRNA(LacZ) control; (d) pRNA/siRNA(GFP); (e)
pRNA/siRNA(mutant); (f) pRNA vector alone (C) Comparison of the
performance of chimeric pRNA/siRNA(GFP) (a) and the conventional
double-stranded -siRNA(GFP) (b) at the same molar concentration. Panel
(c) is the control with no siRNA treatment. (D) Northern blot to exam-
ine the effect of chimeric pRNA/siRNA(GFP) on GFP mRNA level after
transfection. Lanes 1 and 2 show the effects of two different constructs
of pRNA/siRNA(GFP). Lane 3 is the double-stranded siRNA and lane 4
is cells without RNA treatment. rRNA was used as loading control.
Reprinted with permission from [46], S. Guo et al., Human Gene Therapy
16, 1097 (2005). © 2005, Mary Ann Liebert, Inc.
small RNA and folate reported, other materials such as
heavy metal, quantum dots, fluorescent beads or radioiso-
topes can also be conjugated for the detection of cancer
signatures at different stages of development. The conju-
gation of endosome-disrupting chemicals could be used to
promote the release of internalized therapeutic reagent from
the endosome to improve therapeutic efficacy. This polyva-
lent RNA complex can also potentially be used for treat-
ing chronic viral infections through targeting at the specific
virus-glycoproteins displayed on the infected cell surface.
It is well-established in the scientific community that
RNAs do not induce a detectable immune response except
when complexed with proteins.204205 The use of RNA as
a delivery vehicle could avoid the problems of immune
response and the rejection of protein vectors after repeated
long-term drug administration for chronic diseases.
6.3. Construction of Chimeric pRNA Subunit
Harboring Therapeutic Moieties
An important task in constructing chimeric monomers is to
protect the delivered therapeutic molecule from exonucle-
ase degradation, a problem commonly encountered in gene
therapy. Therapeutic RNA molecules are typically vulnera-
ble to RNase digestion. They can be protected by connect-
ing both ends of the foreign RNA with both ends of the
pRNA. Circular permutation strategies were also applied
for this purpose.9293125206 The feasibility of constructing
circularly permuted RNAs lies in the close proximity of
the native 5′ and 3′ ends.104 The feasibility of constructing
functional RNA that harbors actual ribozymes has been
recently demonstrated.20 The monomer pRNA carrying the
foreign daughter RNA molecule can also contain the same
designable right and left loops for the formation of dimers,
trimers, and hexamers. This section describes the construc-
tion of one subunit of the building block of the RNA
nano-particles.
6.3.1. Harboring siRNA
Recently, post-transcriptional gene-silencing and RNA
interference have been investigated extensively in a wide
variety of organisms using double-stranded RNAs.207208
This RNA is processed into small interfering RNAs
(siRNAs) of 19–25 nucleotides,209210 which act as guides
for the formation of the silencing enzymatic complex
required for cleavage of the target mRNAs.77211 These
siRNAs specifically suppress the expression of a target
mRNA with a sequence identical to the siRNA. Although
the detailed mechanism of post-transcriptional gene silenc-
ing and RNA interference remains to be elucidated, this
powerful new technology for selective inhibition of spe-
cific gene expression employing siRNAs has shown great
promise in the therapy of cancer and viral infections.6467
Bacterial phage phi29 pRNA contains a double-stranded
helical domain at 5′/3′ end and an intermolecular binding
domain, which fold independently of each other. Com-
plementary modification studies have revealed that alter-
ing the primary sequences of any nucleotide of the
helical region does not affect pRNA structure and fold-
ing as long as the two strands are paired (Fig. 1).104
Extensive studies revealed that siRNA is a double-stranded
RNA helix.646567209 To test whether it is possible to
replace the helical region in pRNA with double-stranded
siRNA, a variety of chimeric pRNAs with different tar-
gets were constructed to carry siRNA connected to
nucleotides #29 and 91 of the pRNA (Fig. 1), resulting
in pRNA/siRNA(GFP), pRNA/siRNA(Luciferase), and
pRNA/siRNA(Survivin).
Chimeric pRNA/siRNA(GFP) was constructed and the
specific inhibition of GFP expression by this RNA build-
ing block was demonstrated in mRNA and protein level
(Fig. 6). pRNA/siRNA(Luciferase) was another building
block RNA proven to successfully inhibit target gene
expression (Fig. 7). Two chimeric pRNA/siRNA constructs
targeting either firefly luciferase or Renilla luciferase
were found to inhibit target luciferase gene expression
without showing non-specific inhibition to internal con-
trol luciferase gene expression. In addition, chimeric
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Fig. 7. Functional assay of chimeric pRNA/siRNA targeting luciferase
by transfection. (A) Dual reporter luciferase assay showing the spe-
cific knockdown of firefly luciferase or renilla luciferase expression by
pRNA/siRNA(Firefly) or pRNA/siRNA(Renilla), respectively in a dose
dependent manner. (B) Comparison of the activities of the conven-
tional hairpin siRNA(Luciferase) and pRNA/siRNA(Luciferase). pRNA/
siRNA(mutant) with mutations in siRNA sequences was included as a
nonspecific control. Reprinted with permission from [46], S. Guo et al.,
Human Gene Therapy 16, 1097 (2005). © 2005, Mary Ann Liebert, Inc.
pRNA/siRNA exhibited equivalent or superior inhibitory
effects on target gene expression compared with chem-
ically synthesized double-stranded siRNA or hairpin
siRNA (GFP) (Fig. 6). pRNA/siRNA(Survivin) and
pRNA/ribozyme(Survivin) targeting an anti-apoptosis fac-
tor survivin, which is necessary to down-regulate genes
involved in tumor development and progression, was
shown to suppress survivin expression, initiate apoptosis
and cell death (Fig. 8).
6.3.2. Harboring Hammerhead Ribozyme20
Connecting the pRNA 5′/3′ ends with variable sequences
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Fig. 8. Apoptosis and cell death induced by transfection of chimeric
pRNA harboring siRNA targeting survivin. (I) Breast cancer MCF-7 cells
were transfected with pRNA/siRNA(Survivin) and apoptosis was mon-
itored using PI/annexin V double-labeling followed by flow cytometry.
Cells at the lower right quadrant represent apoptotic cells. (II) Breast
cancer cells MDA-231 and prostate cancer cells PC-3 were transfected
with 20 pmol of pRNA/siRNA(Survivin) in 24-well plates and images
were taken in 24 hours after transfection. The mutant pRNA/siRNA was
transfected in parallel as a negative control. Reprinted with permission
from [46], S. Guo et al., Human Gene Therapy 16, 1097 (2005). © 2005,
Mary Ann Liebert, Inc.
features, which help prevent two common problems—
exonuclease degradation and misfolding in the cell, make
pRNA an ideal vector to carry therapeutic RNAs. A pRNA-
based vector was designed to carry hammerhead ribozymes
that cleave the hepatitis B virus (HBV) polyA signal.
The chimeric HBV-targeting ribozyme was connected to
the pRNA 5′/3′ ends as circularly permuted pRNA. Two
cis-cleaving ribozymes were used to flank and process the
chimeric ribozyme. The hammerhead ribozyme includ-
ing its two arms for HBV targeting was able to fold
correctly while escorted by the pRNA. The chimeric
ribozyme cleaved the polyA signal of HBV mRNA in vitro
almost completely. Cell culture studies showed that the
chimeric ribozyme was able to enhance the inhibition of
HBV replication when compared with the ribozyme not
escorted by pRNA, as demonstrated by Northern blot and
e-antigen assays. pRNA could also carry another hammer-
head ribozyme to cleave other RNA substrate.
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6.3.3. Harboring Antisense RNA6869
Antisense RNAs are single-stranded RNA molecules com-
plementary to mRNA. Antisense RNA can inhibit gene
expression in the cell.6869 This applies to the construc-
tion of chimeric RNA monomers carrying single-stranded
antisense RNA. All antisense RNA used to block gene
function are placed at the 3′-end of the pRNA.
6.3.4. Harboring Receptor-Binding Aptamer
To achieve specific delivery of therapeutic complexes, it
is often necessary to incorporate a moiety that recognizes
signature molecules on cell surfaces. In comparison to
antibodies and phage-displayed peptides, RNA aptamer is
an attractive alternative since it avoids the induction of
immune responses.204 Using the SELEX approach, a num-
ber of RNA aptamers were obtained that specifically rec-
ognize a particular cell surface receptor such as CD4.203
One CD4-binding RNA aptamer was chosen to construct
chimeric pRNA/aptamer(CD4) via a mutual 5′/3′ e d con-
nection (Fig. 1D). The pRNA vector was reorganized into
a circularly permuted form, with the nascent 5′ and 3′
ends relocated to residues #71 and 75, respectively, of the
original pRNA sequence. The 71/75 end is located in a
tightly-folded area135 to bury and protect the ends from
exonuclease degradation in vivo.20
6.3.5. Adding Drugs, Folate, or Other Chemical
Moieties or Groups to RNA
Some cancer cells overexpress the receptor for folate,
which has been shown to be a useful target for the spe-
cific delivery of drugs in cancer therapy.212213 Other drugs
might be incorporated into the therapeutic complex to
enhance the therapeutic effect. Chemicals for image detec-
tion or endosomal disruption can also be connected to the
RNA complex. Therefore, it is desirable to have simple
and efficient methods for the conjugation of such groups
to RNA. Such additions include labeling with pCp, DIG,
phosphate, as well as biotin, amine, sulfhydryl, and car-
boxyl groups, which are simple and efficient groups for
conjugation. NHS can be used to covalently link particles
with a primary amine group. NH2-group can be used to
link any particles with a COOH group with the help of
EDC, or with Cysteine or SH-group using a variety of
amine and sulfhydryl reactive heterobifunctional cross-
linkers such as BMPS. Sulfhydryl-groups can be used to
link NH2-groups via BMPS or with any common chem-
icals that contain maleimide. Maleimide can be used to
link covalently with any particles that contain SH-group.
In addition, NH2/NH2 interaction can be achieved via com-
mercially available heterobifunctional crosslinkers as well.
Folate receptors are over-expressed in various types
of tumors such as human nasopharyngeal epidermal
carcinoma but are generally absent in normal adult tissues.
The folate molecule, which binds to folate receptor with
I.Assay for co-entry of 3 RNAs in trimer
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Fig. 9. Confocal microscopy showing the specific and simultaneous
delivery of three components to CD4 over-expressing cells. (I) Assay
for the binding of pRNA trimer containing pRNA(A-b′)/aptamer(CD4),
pRNA(B-e′)-FITC, and pRNA(E-a′)-Rhodamine to CD4 over-expressing
T cells (A–D of left column, and I–L of right column) and CD4 negative
cells T cells (E–H of middle column). A, E, and I were imaged with an
FITC filter; whereas B, F, and J were viewed with a Rhodamine filter;
C, G, and K are overlays; and D, H, and L are DIC images. The right
column represents a close-up view of CD4 over-expressing cells. Arrows
point to the complexes that had entered the cell. (II) Section of confocal
microscopy images to differentiate between binding (M) and cell entry
(arrows in N and O) as well as negative control (P). Binding of FITC-
labeled pRNA trimer containing CD4-binding aptamer to lymphocytes
was shown as a circle and entry was shown as a green spot inside cell
(arrow in O). The red color in N is a positive entry control of transferrin
labeled with Texas red. Reprinted with permission from [47], A. Khaled
et al., Nano Lett. 5, 1797 (2005). © 2005, American Chemical Society.
high affinity, was incorporated into the 5′ end of RNA
by in vitro transcription using folate-AMP. Specific cell
binding of pRNA/folate dimer was demonstrated by incu-
bating folate receptor positive KB cells with dimeric
pRNA which contains a folate labeled pRNA(A-b′) and a
[H3]-pRNA(B-a′). Then the nanoparticles containing both
folate-labeling and chimeric pRNA/siRNA were shown to
knockdown the firefly luciferase gene expression by a sim-
ple incubation process (Fig. 10). Furthermore, animal tri-
als were performed to demonstrate specific suppression
of tumorigenicity of cancer cells by ex vivo delivery
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Fig. 10. Specific delivery of chimeric pRNA/siRNA by folate-pRNA. (A) Flow cytometry analyses of the binding of folate-pRNA-FITC to KB cells.
Cells were incubated with folate-pRNA labeled with FITC (left panel). Cells in the middle panel were pre-incubated with free folate, which served
as a blocking agent to compete with folate-pRNA for binding to the receptor. Binding was also tested using folate-free pRNA labeled with FITC
(right panel) as a negative control. The percentages of FITC-positive cells are shown in the upper right quadrants. (B) Specific binding of folate-pRNA
dimer to KB cells. After incubation of cells with the [3H]-folate-pRNA dimer in the presence (center column) or absence (left column) of free folate,
cells were isolated and subjected to scintillation counting. The right column is the [3H]-dimer without folate labeling as a negative control. (C) In the
knockdown assay by incubation, folate-chimeric dimer complex containing pRNA(B-a′)/folate and pRNA(A-b′)/siRNA(firefly) was incubated with KB
cells for 3 hours to allow the binding and entry of RNA. The luciferase level was measured in the next day by the dual reporter system. The control
dimer was identical to the folate dimer except for its lack of folate labeling. Reprinted with permission from [46], S. Guo et al., Human Gene Therapy
16, 1097 (2005). © 2005, Mary Ann Liebert, Inc.
of the nano-particle containing both folate labeling and
chimeric pRNA/siRNA against survivin. The potential of
this RNA complex to suppress tumor formation was tested
in athymic nude mice. Human nasopharyngeal epidermal
carcinoma KB cells were incubated with a chimeric RNA
complex with or without folate before being introduced
into the nude mice by axilla injection. The mice receiving
only cancer cells developed tumors within 3 weeks, while
the group of mice that received cancer cells pre-treated
with the pRNA complex containing both folate-pRNA and
pRNA/siRNA(Survivin) did not develop tumors (Fig. 11).
The inhibition of tumor formation is specific since the
control RNA complex without folate or the RNA com-
plex containing mutations in survivin siRNA did not affect
tumor development in other mice groups.
6.4. Assembly of Deliverable Dimeric, Trimeric
Therapeutic RNA Nano-Particles
RNA nano-particles containing two or three chimeric
RNA building blocks were constructed. Nano-particles
carry multiple components, including molecules for spe-
cific cell recognition, image detection, and therapeutic























Fig. 11. Animal trials for cancer therapy using the fabricated RNA
nanoparticles. (A) Injection without the pRNA/siRNA chimera (No
RNA); (B) Treatment with RNA chimera containing folate-pRNA and
siRNA(Survivin); (C) Treatment with RNA chimera containing folate-
pRNA and siRNA(Survivin) with mutations in the siRNA sequence;
(D) Treatment with pRNA-siRNA chimera that does not contain a folate
at its 5′ end. Reprinted with permission from [47], A. Khaled et al., Nano
Lett. 5, 1797 (2005). © 2005, American Chemical Society.
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Fig. 12. The potential use of pRNA hexamers as polyvalent gene deliv-
ery vectors. Six copies of pRNA have been found to form a hexameric
ring to drive the DNA-packaging motor of bacterial virus phi29. There
would therefore be six positions available to carry foreign moieties for
targeting, therapy, and detection, as shown in the figure. Reprinted with
permission from [46], S. Guo et al., Human Gene Therapy 16, 1097
(2005). © 2005, Mary Ann Liebert, Inc.
(dimer, trimer) was modified to carry an RNA aptamer
or other receptor binding ligands that bind a specific cell-
surface receptor, thereby inducing receptor-mediated endo-
cytosis. The second subunit carried reporting molecules
such as fluorescent beads. The third subunit was altered to
carry therapeutic siRNA, ribozyme RNAs, antisense RNA,
or other drugs to be delivered.47
6.5. Sequence Requirement of the Hand-in-Hand
Loops in Chimeric Trimer Formation
Bases 45–48 and 82–85 of wild type pRNA in the left-
and right-hand loops, respectively, were found to engage
in pRNA/pRNA interactions.131166 Without considering
tertiary interaction, in some cases only two G/C pairs
between the interacting loops could allow the forma-
tion of pRNA multimers. When all four nucleotides were
paired, at least one G/C pair was required. The maxi-
mum number of base pairings between the two loops to
allow optimal polymer formation was five. The minimum
number of nucleotides needed for pRNA/pRNA interaction
in the right and left loop was five and three, respectively.
Our results suggest that a 75-nucleotide RNA segment,
nucleotide 23–97, is a self-folded independent domain
involved in RNA/RNA interaction in pRNA trimer forma-
tion, while nucleotide 1–22 and 98–120 were dispensable
for RNA/RNA interaction.
The mechanism of pRNA trimer formation by interlock-
ing loop/loop interaction was utilized for the fabrication of
the trimer of chimeric pRNA harboring receptor-binding
RNA aptamer and/or therapeutic siRNA (Fig. 9). Indi-
vidual chimeric pRNA building block was engineered to
carry one daughter RNA molecule such as siRNA or
receptor-binding aptamer. Each building block was inten-
tionally designed to have specific right or left loops, such
as A-b′ (right–left), to interact with other building block.
The appropriate folding of pRNA and their competency
in forming trimers were confirmed. Mixing of individual
chimeric pRNAs with counterpart partners with appropri-
ate interlocking loops resulted in the efficient formation
of the desired trimer, as documented by gel electrophore-
sis, AFM imaging, and sucrose gradient sedimentation.
This suggests that RNA trimers were generated from the
monomeric building block despite the replacement of the
5′/3′ helix with ds-siRNA or the connection of the 5′/3′
end to a CD4-binding aptamer.
6.6. Confirmation of Binding and Entry of the
Nano-Particles into Cells
To determine whether RNA can serve as an effective vehi-
cle for the concurrently delivery of multiple therapeu-
tic particles, a trimeric pRNA/aptamer(CD4) complex was
constructed and additional components were added to it in
order to demonstrate the successful binding and entry of
the multivalent complex into cells. In this trimer, one of the
subunits was the pRNA(A-b′) chimera harboring the CD4-
binding aptamer. The other two subunits carry the FITC
(green) molecule and Rhodamine (orange label) molecule,
respectively. To test the binding and entry of the trimer,
a confocus section approach was attempted with the use
of difference filters (Fig. 9). Binding of the trimer to the
cells was demonstrated by the finding that fluorescence
color appeared on the cell surface as a circle, which is
one layer of the cell from the confocal microscope. Entry
of the trimer into the cell via CD4-mediated endocyto-
sis was demonstrated by the appearance of a fluorescence
spot within the cell (Figs. 9A, B, K, and L). Such bind-
ing and entry was specific as long as CD4 was present,
since no fluorescence was observed on CD4-negative cells
(Fig. 9-I, lower panel). The appearance of both types of
fluorescence on the cell surface suggests that pRNA(B-c′)
and pRNA(C-a′) had been conjugated onto CD4-binding
aptamer A-b′, which had no fluorescence label but had
the capacity for CD4 binding. Figures 9K–L, when com-
pared with Texas Red-labeled transferrin as the positive
control for entry (Fig. 9J), further illustrates the success
in entry. The similarity and overlap of the FITC image
with the rhodamine image in Figures 9K–L strongly indi-
cates that the FITC-labeled pRNA(B-c′) had combined
with the rhodamine-labeled pRNA(C-a′) and been co-
delivered to the cell. All of these results indicate that RNA
trimers can serve for the delivery of multiple therapeutic
components.
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7. PERSPECTIVES
Phi29 pRNA has a strong tendency to form dimers,
trimers, and hexamers due to the interaction of the inter-
locking right- and left-hand loops, which are maneuverable
and controllable. It has been shown that insertion of a
ribozyme or siRNA at pRNA’s 3′/5′ paired ends does not
interfere with the folding of the pRNA itself, the ribozyme
or the siRNA. In addition, it also does not affect the
formation of dimers, trimers, and hexamers. Instead, the
pRNA can escorte the ribozyme or siRNA to destroy Hep-
atitis B virus or cancer cells. These features enable the
development of several new approaches for prostate cancer
detection and treatment. The formation of defined pRNA
multimers, which are controllable through the design of
complementary interlocking loop sequences, will allow
for the construction of detection and delivery vehicles.
These vehicles will carry multiple components, includ-
ing molecules for specific cell recognition, image detec-
tion, endosome disruption, and therapeutic treatment. For
example, in hexameric complex, one subunit of the deliv-
erable RNA complex (dimer, trimer, or hexamer) will be
modified to carry an RNA aptamer that binds a specific
cell-surface receptor, thereby inducing receptor-mediated
endocytosis. The second subunit of the hexamer will carry
reporting molecules like heavy metal complexes, quantum
dots, fluorescent beads, or radioisotopes for prostate can-
cer detection. The third subunit of the hexamer will be
altered to carry components that will be used to enhance
endosome disruption so that the therapeutic molecules are
released. The fourth and fifth subunits of the RNA com-
plex will carry therapeutic siRNA, ribozyme, antisense
RNA, or other drugs to be delivered. The sixth subunit
of the hexamer will be designed to allow for the detec-
tion of apoptosis, the planned outcome of this treatment.
Although phi29 motor pRNA is unusually stable and the
formation of hexamer makes the complex more resistant to
RNAase digestion due to the intertwining nature, further
procedure to enhance the stability of the RNA complex in
blood stream is still needed. Nucleotide derivatives, such
as 2′-F-pyrimidine214 or spiegelmer,215 will be incorporated
into the RNA to produce stable in vitro RNA transcripts
that are resistant to RNase digestion. Other nucleotides
with lower cell toxicity will be further developed to
enhance safely of this therapeutic reagent produced by
RNA nanotechnology.
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